These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34530706)

  • 1. Interactions between ACE2 and SARS-CoV-2 S Protein: Peptide Inhibitors for Potential Drug Developments Against COVID-19.
    Dërmaku-Sopjani M; Sopjani M
    Curr Protein Pept Sci; 2021; 22(10):729-744. PubMed ID: 34530706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
    Ahmad I; Pawara R; Surana S; Patel H
    Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor.
    Odolczyk N; Marzec E; Winiewska-Szajewska M; Poznański J; Zielenkiewicz P
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33918595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
    Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
    Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Natural Bioactive Peptide from
    Wang Y; Wang Q; Chen X; Li B; Zhang Z; Yao L; Liu X; Zhang R
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
    Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
    Elife; 2020 Oct; 9():. PubMed ID: 33103998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide S4 is an entry inhibitor of SARS-CoV-2 infection.
    Liang Z; Wang J; Zhang H; Gao L; Xu J; Li P; Yang J; Fu X; Duan H; Liu J; Liu T; Ma W; Wu K
    Virology; 2024 Sep; 597():110149. PubMed ID: 38917689
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.